Around 500,000 individuals worldwide endure mind aneurysms yearly, placing them liable to paralysis or deaths, in line with a Turkish biotech agency that has developed probably the most efficient therapies for the problem.
Aneurysms are prompted when an artery wall weakens, making a bulge that may burst and result in deadly penalties.
Turkish biotech agency INVAMED Medical Device Technologies has developed its Libro Liquid Embolic System to deal with aneurysms in cerebral vessels or peripheral arteries, in addition to different vascular malformations.
Its profitable outcomes have helped it stand out and achieve widespread recognition as an efficient therapy methodology, in line with an INVAMED assertion.
“It is composed of EVOH (ethylene vinyl alcohol copolymer) with suspended micronized Tantalum powder for radiopacity and DMSO (dimethyl sulfoxide) solvent that provides complete filling and distal penetration of peripheral and neurovascular lesions,” the agency mentioned.
“Its non-adhesive properties permit more distal nidus embolization without significant risk of catheter entrapment, while higher viscosities allow for controlled deployment,” it added.
The DMSO solvent “dissipates into the blood, causing the EVOH copolymer and suspended tantalum to precipitate in situ into a spongy, coherent embolus,” the assertion defined.
